On September 7, the ME/CFS community breathed a sigh of relief as the Senate Appropriations Committee passed S. 1711 with accompanying committee report language that recommends restoring the $5.4 million Chronic Fatigue Syndrome program under the CDC’s National Center for Emerging and Zoonotic Diseases.
In July, the House version of the budget (H.R. 3358) had zeroed out these funds in the House Committee report. Both the House and Senate reports include several recommendations to CDC, NIH, and HHS that were proposed by #MEAction, Solve ME/CFS Initiative, and other advocates during the May ME/CFS Advocacy Week.
We are pleased to see this support and growth of interest reflected in the Senate appropriations bills and look forward to continuing to fight for these items to be included after the reconciliation process in the final budget legislation in October.
This restored funding will not be official until the final budget is passed by October 1st. Some staffers expect there will be no budget compromise this year, but rather a continuing resolution that will repeat funding expenditures agreed upon in Fiscal Year 2015.
Why We Keep Telling the Story of ME to the Press
Our press work continues to drum a strong beat as we tell the story of ME everyday to the media. We will continue to fight for our community’s decades of expertise living with, treating and researching ME to be heard, and integrated into our government’s Long COVID response. We refused to be erased from the
2 thoughts on “Senate Appropriations Committee Recommends Restoring ME/CFS Funding”
I looked at the link to the Sept. appropriations bill, but didn’t see where $5.4 million for ME/CFS is funded. Is it in the total for NIH?
Hi Carol –
The $5.4 million is included as part of the CDC’s program program in the National Center for Emerging and Zoonotic Diseases. It is in that total. That amount is specified in the Committee report. The NIH funding is established separately. There is no Congressional line item for ME/CFS funding at the NIH.
Hope this helps!
Comments are closed.